Buz Investors Ubiquitech Gives Fiscal Year 2017 Revenue Guidance - Mar 23, 2017) - Ubiquitech Software Corp. (OTC PINK: UBQU), through its operating subsidiary HempLifeToday.com, is announcing fiscal year 2017 revenue guidance.
Market Trends

Ubiquitech Gives Fiscal Year 2017 Revenue Guidance; Anticipates 55% Year Over Year Increase To $5,450,000

Ubiquitech Gives Fiscal Year 2017 Revenue Guidance Buz Investors Ubiquitech Gives Fiscal Year 2017 Revenue Guidance– Mar 23, 2017) – Ubiquitech Software Corp. (OTC PINK: UBQU), through its operating subsidiary HempLifeToday.com, is announcing fiscal year 2017 revenue guidance. The company anticipates that revenues for the year ending November 30, 2017 will increase over 55% from […]

Buz Investors Coupa Software Reports Fourth Quarter (NASDAQ:COUP), a leader in cloud-based spend management, today announced its financial results for the fourth quarter and fiscal year-ended January 31, 2017.
Market Trends

Coupa Software Reports Fourth Quarter & Full Year Fiscal 2017 Financial Results

Coupa Software Reports Fourth Quarter & Full Year Fiscal 2017 Financial Results  Record Full Year Revenue of $134 Million  Cumulative Spend Under Management Surpasses $360 Billion Buz Investors Coupa Software Reports Fourth Quarter  (NASDAQ:COUP), a leader in cloud-based spend management, today announced its financial results for the fourth quarter and fiscal year-ended January 31, 2017. […]

Buz Investors Tabula Rasa HealthCare (“TRHC”) (NASDAQ:TRHC), a disruptive innovation and technology leader in medication safety, offering a unique Medication
Earnings

Tabula Rasa HealthCare Announces Fourth Quarter and Full Year 2016 Operating Results

Tabula Rasa HealthCare Announces Fourth Quarter and Full Year 2016 Operating Results 2016 Revenue of $94.1 million, growth of 34%; 4Q 2016 Revenue of $27.3 million, growth of 38% Buz Investors Tabula Rasa HealthCare (“TRHC”) (NASDAQ:TRHC), a disruptive innovation and technology leader in medication safety, offering a unique Medication Risk Stratification and Medication Risk Mitigation […]